



Daily Derivatives

21 September, 2026

DERIVATIVES

21 September 2026

**Daily
Derivatives**

Key Indices

Index	Close	Changes (%)
NIFTY	23346.40	0.33
SENSEX	74294.96	-0.03
BANKNIFTY	56358.70	0.54
INDIA VIX	11.39	-7.36

Market Outlook

The key benchmark Nifty50 index extended its decline for the sixth consecutive week; however, the fall remained marginal as the index showed resilience near the crucial 23,000-23,100 zone and witnessed a relief bounce from these levels. On the derivatives front, significant put writing was observed at the 23,000 and 23,200 strikes, indicating an immediate base formation. On the upside, notable call writing remains aligned at the 23,500 and 23,600 strikes, highlighting an immediate overhead resistance area. Overall, a sell-on-rally bias remains intact as long as Nifty sustains below this resistance zone.



TRADE IDEA OF THE DAY - MAXHEALTH

BUY 29 SEP 1050 CALL

Entry Range	12 -15
Target	35
Stop Loss	6.5



Rationale

- MAXHEALTH has maintained a positive structure on the daily chart, as the stock has recently reclaimed its key moving averages of the 20-DEMA as well as the 50-DEMA, indicating improving buying interest and strengthening momentum.
- The stock has taken support near its rising trendline, as the stock price has formed a higher bottom structure on the daily timeframe. Sustained trading above the 1,020-10350 zone keeps the broader bullish structure intact and provides a favorable base for further upside.
- Momentum indicators are supportive, with RSI hovering near the 60 mark and moving higher, while the MACD has turned positive with a bullish crossover, indicating strengthening momentum and scope for continuation of the recent recovery.
- On the upside, sustained buying above the immediate support zone could trigger a move towards 1,090-1,100, followed by 1,140. Any dip towards the support zone may attract fresh buying interest, and the 980 -1,000 zone holds strong downside support.

21 September 2026

Daily
Derivatives


NIFTY

LTP (Future)	23380.00
OI (In Lots)	271852
CHANGE IN OI (%)	0.02
PRICE CHANGE (%)	0.20


BANKNIFTY

LTP (Future)	56539.00
OI (In Lots)	68314
CHANGE IN OI (%)	-3.17
PRICE CHANGE (%)	0.41


NIFTY OI



BANKNIFTY OI



FII's Activity Index Futures



FII's Long Short Ratio



Long Buildup

Name	LTP	% Change	OI (Lots)	% OI Change
UNOMINDA	1242	3.06	11181	13.47
ATHERENERG	1607.5	3.84	12885	11.76
ADANIPTS	1778.3	2.41	36157	8.53
BPCL	313.5	1.79	16541	7.79

Short Buildup

Name	LTP	% Change	OI (Lots)	% OI Change
NESTLEIND	1367	-0.86	19812	10.89
TCS	2095	-4.40	133885	8.32
LTM	4206	-0.63	32768	7.33
TMPV	302.9	-4.13	53750	7.24

Breakout Stocks (1 Month High)

Name	LTP	% Change	22 DAY HIGH
MAXHEALTH	1051.3	1.37	1045
-	-	-	-
-	-	-	-
-	-	-	-

Breakdown Stocks (1 Month Low)

Name	LTP	% Change	22 DAY LOW
TCS	2098.2	-4.26	2168.6
KPITTECH	539.25	-3.52	546.95
TATAELXSI	3314.5	-2.06	3357.5
ICICIBANK	1343.4	-0.96	1354

21 September 2026

Daily
Derivatives

NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	LTP*	S1*	S2*
ADANIENT	3052	3084	3020	2956	2893
ADANIPTS	1851	1877	1824	1771	1717
APOLLOHOSP	8993	9042	8944.5	8847	8749
ASIANPAINT	2471	2490	2451.3	2435	2418
AXISBANK	1263	1268	1257	1246	1235
BAJAJ-AUTO	11501	11587	11414	11367	11319
BAJAJFINSV	1866	1879	1852.5	1846	1839
BAJFINANCE	1047	1054	1040.3	1026	1012
BEL	397	401	393.3	391	389
BHARTIARTL	1913	1932	1893.3	1855	1816
CIPLA	1402	1410	1394.5	1379	1364
COALINDIA	417	423	409.9	406	403
DRREDDY	1201	1217	1185	1176	1166
EICHERMOT	7564	7613	7516	7472	7429
ETERNAL	329	331	326.85	325	323
GRASIM	3221	3232	3209.2	3186	3163
HCLTECH	1262	1274	1249.3	1236	1223
HDFCBANK	738	745	731	720	708
HDFCLIFE	560	570	550.95	546	542
HINDALCO	997	1008	986.5	978	969
HINDUNILVR	1950	1969	1932	1923	1914
ICICIBANK	1353	1367	1338.9	1332	1325
INDIGO	4966	5013	4920	4877	4835
INFY	1063	1074	1051.4	1039	1027
ITC	265	268	262.3	261	259

*R1 - Resistance 1 | *R2 - Resistance 2 | *LTP – Last Traded Price | *S1 - Support 1 | *S2 - Support 2

21 September 2026

Daily Derivatives

NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	LTP*	S1*	S2*
JIOFIN	231	233	229.89	229	228
JSWSTEEL	1282	1288	1275.6	1266	1256
KOTAKBANK	417	421	412.5	410	408
LT	3907	3928	3885	3855	3824
M&M	3083	3114	3052	3037	3021
MARUTI	12340	12576	12103	11985	11866
MAXHEALTH	1061	1073	1049.3	1036	1023
NESTLEIND	1397	1422	1372.4	1340	1308
NTPC	328	333	323.65	321	319
ONGC	234	236	232.8	232	230
POWERGRID	273	275	270.3	266	261
RELIANCE	1240	1254	1226.4	1219	1212
SBILIFE	1757	1783	1731	1718	1705
SBIN	1000	1004	996.2	989	981
SHRIRAMFIN	1019	1028	1010	1001	991
SUNPHARMA	1864	1891	1837.3	1824	1811
TATACONSUM	1011	1026	996	988	981
TATASTEEL	187	189	185.54	185	184
TCS	2154	2204	2105	2078	2052
TECHM	1558	1579	1537.1	1520	1502
TITAN	4851	4904	4798.5	4759	4719
TMPV	309	314	303.8	300	297
TRENT	2840	2856	2824	2792	2760
ULTRACEMCO	11110	11205	11014	10869	10723
WIPRO	168	169	166.83	164	162

*R1 - Resistance 1 | *R2 - Resistance 2 | *LTP – Last Traded Price | *S1 - Support 1 | *S2 - Support 2

Our Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Rajan Gupta	rajan.gupta1@religare.com
Vivek Chandra	vivek.chandra@religare.com
Himanshu Gupta	himanshu.gupta1@religare.com

21 September 2026

Daily
Derivatives

Before you use this research report, please ensure to go through the disclosure interalia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

S.No.	Statement	Answer	
		Tick Appropriate	
		Yes	No
1.	I/we or any of my/our relative has any financial interest in the subject company? (If answer is yes, nature of interest is given below this table)		No
2.	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of the research report or date of the public appearance?		No
3.	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of the public appearance?		
4.	I/we have received any compensation from the subject company in the past twelve months?		No
5.	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
6.	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
7.	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
8.	I/we have served as an officer, director or employee of the subject company?		No
9.	I/we have been engaged in market making activity for the subject company?		No

2014 is/are as under:

Statements of ownership and material conflicts of interest, compensation – Research Analyst (RA)

Nature of Interest [If answer to f (a) above conflicts is Yes

.....]

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to

Copyright: This document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.